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Background: Diabetes mellitus has been associated with an increased risk of bladder cancer, although the evidence is still open
to discussion.
Methods: We examined this association using data from a multicentre Italian case–control study, conducted between 2003 and
2014 on 690 bladder cancer cases and 665 frequency-matched hospital controls. Odds ratios (ORs) for diabetes were estimated by
unconditional multiple logistic regression models, after allowance for major known risk factors for bladder cancer.
Results: One hundred and twelve (16.2%) cases and 57 (8.6%) controls reported a diagnosis of diabetes mellitus, corresponding to
a multivariate OR of 2.09 (95% confidence interval (CI): 1.46–3.01). Bladder cancer risk increased with duration of diabetes (OR 1.92
for 1–o5 years, 1.63 for 5–o10 years, 2.39 for 10–o15 years, and 2.58 for X15 years). The increased risk of bladder cancer was
consistent in strata of age and education, whereas it was somewhat lower (although not significantly) in women (OR 1.18), in never
(OR 1.31) and current (OR 1.42) smokers, and in subjects with a body mass index o25 kgm 2 (OR 1.48).
Conclusion: The present study provides further support of a role of diabetes in bladder cancer aetiology, although some residual
confounding by tobacco, body mass index, or other unmeasured covariates may partly explain the association observed.
In the European Union, bladder cancer is the fifth most common
cancer type and the ninth leading cause of cancer mortality, with
about 40 000 deaths every year (Ferlay et al, 2013; Bosetti et al,
2013a). Its major recognised risk factor is tobacco smoking, with
smokers having a three- to four-fold excess risk as compared with
never smokers (Zeegers et al, 2000; IARC, 2004). Other known risk
factors for bladder cancer include exposures to a few industrial
chemicals (mainly aromatic amines in the past), drinking water
contaminants, phenacetin-containing analgesics, and possibly
selected aspects of diet (Villanueva et al, 2004; Silverman et al,
2006; World Cancer Research Fund and American Institute for
Cancer Research, 2007; Letasiova et al, 2012).
Diabetes mellitus – an important determinant of various
common neoplasms (Renehan et al, 2010) – has also been
associated with an increased risk of bladder cancer, although the
evidence is still open to discussion (Larsson et al, 2006; Newton
et al, 2013; Prizment et al, 2013; Zhu et al, 2013a, b; Cantiello et al,
2015). A meta-analysis conducted in 2006 on seven case–control
studies, three cohort studies, and six cohort studies in diabetic
patients reported an overall relative risk (RR) of 1.24
(95% confidence interval (CI): 1.08–1.42), with a consistent RR in
case–control studies (RR 1.37) and in cohort studies (RR 1.43), but
no association in the cohorts of diabetic patients (RR 1.01)
(Larsson et al, 2006). Consistent results were reported in two
subsequent meta-analyses based on at least 9 case–control studies
and 29 cohort studies, with pooled RRs ranging between 1.35 and
1.45 (Zhu et al, 2013a, b). A few studies examining the duration-
risk relationship reported conflicting results (Atchison et al, 2011;
MacKenzie et al, 2011; Tseng, 2011; Newton et al, 2013; Prizment
et al, 2013).
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We further examined the association between diabetes and
bladder cancer risk using data from a multicentre Italian case–
control study (Polesel et al, 2014), where information was also
available on age at diabetes diagnosis.
MATERIALS AND METHODS
Study participants and data collection. Between 2003 and 2014,
we conducted a case–control study on bladder cancer within an
established Italian network of collaborating centres, including
Aviano and Milan in northern Italy, and Naples and Catania in
southern Italy (Polesel et al, 2014). Cases were 690 subjects
(median age 67 years; range 25–84 years) with incident transitional
cell carcinoma of the bladder admitted to major general hospitals
in the study areas. Nearly all bladder cancers (n¼ 642, 93.0%) were
confirmed by histological testing on tumour tissue specimen from
biopsy or surgery and three additional cases were confirmed by
cytology only. Overall, 268 cancers (38.8%) were noninvasive
(i.e., TNM pTis/Ta) and 351 (50.9%) locally invasive (other T); 307
(44.5%) were well or moderately differentiated (grading, G1–G2)
and 312 (45.2%) poorly differentiated or undifferentiated (G3–G4).
Controls were subjects admitted to the same network of hospitals
as cases for a wide spectrum of acute, non-neoplastic conditions
unrelated to tobacco, and alcohol consumption or long-term diet
modification. The control group included 690 patients frequency-
matched to cases by study centre, sex, and 5-year age group.
Twenty-five controls were excluded after enrolment because of
inappropriate admission diagnosis, thus leaving 665 eligible
controls (median age 66 years; range 27–84 years). Overall,
28.9% of controls were admitted for traumas, 22.1% for non-
traumatic orthopaedic disorders, 39.3% for acute surgical condi-
tions, and 9.8% for miscellaneous other illnesses. All study subjects
signed an informed consent, according to the recommendations of
the Board of Ethics of the study hospitals.
Trained interviewers administered a structured questionnaire to
cases and controls during their hospital stay. Refusal was below 5%
for both cases and controls. The questionnaire collected informa-
tion on sociodemographic factors, lifetime smoking and alcohol
drinking habits, habitual diet before diagnosis/interview, a
problem-oriented medical history, family history of cancer, lifetime
occupational history, and exposure to selected chemical substances.
Diagnosis of diabetes mellitus and selected other medical
conditions (confirmed by a physician) was self-reported and
included age at first diagnosis.
Statistical analysis. Odds ratios (OR) according to diabetes, and
the corresponding 95% CI, were estimated by unconditional
multiple logistic regression models (Breslow and Day, 1980),
including terms for study centre, sex, quinquennia of age, year of
interview, education (o7, 7–11,X12 years), and tobacco smoking
(never, ex-smokers, current smokers of o15, current smokers of
15–24, current smokers of X25 cigarettes per day). Additional
models were used to assess the potential modifying effect of
selected covariates and heterogeneity was tested computing the
difference in  2 log-likelihood of the models with and without the
interaction terms. Percent attributable risks were computed using
the distribution of risk factors among bladder cases (Bruzzi et al,
1985). All statistical analyses were performed with SAS 9.2
statistical software (SAS Institute, Cary, NC, USA).
RESULTS
Table 1 gives the distribution of bladder cancer cases and controls
according to selected variables. Cases and controls had a similar
distribution by study centre, sex, and education; cases were slightly
older and more frequently smokers than controls.
One hundred and twelve (16.2%) cases and 57 (8.6%) controls
reported a diagnosis of diabetes mellitus, corresponding to
a multivariate OR of 2.09 (95% CI: 1.46–3.01; Table 2). Further
adjustments for body mass index (BMI), alcohol drinking, history
of cystitis, and family history of bladder cancer did not
meaningfully modify our results. The ORs for diabetes were
similar for well/moderately differentiated (OR 2.11; 95% CI:
1.34–3.33) and poorly differentiated/not differentiated (OR 1.98;
Table 1. Distribution of 690 cases of bladder cancer and 665
controls according to centre, sex, age, and other selected
variables (Italy, 2003–2014)
Cases Controls
No. % No. % P-valuea
Centre
Aviano 242 35.1 250 37.6
Milan 241 34.9 238 35.8
Naples 129 18.7 100 15.0
Catania 78 11.3 77 11.6 0.34
Sex
Men 595 86.2 561 84.4
Women 95 13.8 104 15.6 0.33
Age (years)
o60 148 21.5 178 26.8
60–64 107 15.5 119 17.9
65–69 164 23.8 147 22.1
70–74 155 22.5 124 18.7
X75 116 16.8 97 14.6 0.061
Education (years)b
o7 292 42.4 273 41.1
7–11 224 32.5 215 32.3




96 14.1 237 35.6
Ex-smokers 310 45.5 284 42.7
Current smokers (cigarettes per day)
o15 79 11.6 53 8.0
15–24 127 18.7 68 10.2
X25 69 10.1 23 3.5 o0.001
aP-value for association from w2 statistic.
bThe sum does not add up to the total because of some missing values.
Table 2. ORs of bladder cancer and corresponding 95% CIs
according to history of diabetes mellitus (Italy, 2003–2014)
Cases (%) Controls (%) ORa (95% CI)
Diabetes
No 578 (83.8) 608 (91.4) 1b
Yes 112 (16.2) 57 (8.6) 2.09 (1.46–3.01)
Age at diabetes (years)
o40 6 (0.9) 2 (0.3) 2.81 (0.52–15.1)
X40 106 (15.4) 55 (8.3) 2.06 (1.43–2.99)
Duration of diabetes (years)
1–o5 37 (5.4) 19 (2.9) 1.92 (1.06–3.48)
5–o10 18 (2.6) 14 (2.1) 1.63 (0.77–3.44)
10–o15 21 (3.0) 10 (1.5) 2.39 (1.07–5.33)
X15 36 (5.2) 14 (3.6) 2.58 (1.32–5.03)
w2trend (P-value) 14.67 (o0.001)
Abbreviations: CI¼ confidence interval; OR¼odds ratios.
aAdjusted for study centre, sex, age, year of interview, education, and tobacco smoking.
bReference category.
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95% CI: 1.28–3.06) bladder cancers and for noninvasive (OR 2.39;
95% CI: 1.52–3.75) or locally invasive (OR 1.75; 95% CI: 1.13–2.71)
ones. Similar ORs were observed for those with a diagnosis before
age 40 years (OR 2.81; 95% CI: 0.52–15.1) or at age 40 years or
more (OR 2.06; 95% CI: 1.43–2.99), although the former OR was
based on very few diabetic subjects (six cases and two controls).
Bladder cancer risk increased with duration of diabetes (OR 1.92,
95% CI: 1.06–3.48 for 1–o5 years; 1.63, 95% CI: 0.77–3.44 for
5–o10 years; 2.39, 95% CI: 1.07–5.33 for 10–o15 years; and 2.58,
95% CI: 1.32–5.03 for X15 years).
The risk of bladder cancer was consistent in the strata of age and
education, whereas it was somewhat lower (although not signifi-
cantly) in women (OR 1.18; 95% CI: 0.39–3.63) compared with that
in men (OR 2.29; 95% CI: 1.55–3.39), in never (OR 1.31; 95% CI:
0.56–3.06) and current (OR 1.42; 95% CI: 0.68–2.97) smokers
compared with that in ex-smokers (OR 2.89; 95% CI: 1.75–4.76),
and in subjects with a BMI o25 kgm 2 (OR 1.48; 95% CI: 0.79–
2.80) compared with that in subjects with a BMI X25 kgm 2 (OR
2.55; 95% CI: 1.62–4.01; data not shown in tables). In this
population, 8.4% of all bladder cancers were attributable to diabetes.
DISCUSSION
The present study provides further evidence of the importance of
diabetes in bladder cancer risk, diabetics having about two-fold
excess risk as compared with non-diabetics. A duration-risk
relationship was also observed, which supports a causal role of
diabetes on this neoplasm.
The RR of bladder cancer found in our study is somewhat
higher than the overall risk estimates reported in some meta-
analyses (Larsson et al, 2006; Zhu et al, 2013a, b), which ranged
between 1.2 and 1.5. Tobacco smoking – which is the major
recognised risk factor for bladder cancer (IARC, 2004) and has
been directly associated with diabetes (Willi et al, 2007) – was
allowed for in the models and did not appear to confound
appreciably the association between diabetes and bladder cancer
risk in this dataset. However, a stronger excess risk of bladder
cancer for diabetes was found in former smokers – likely subjects
quitting because of cancer or other health conditions (Gallus et al,
2013) – pointing to a possible residual confounding of tobacco
smoking. Overweight is a strong determinant of type 2 diabetes,
although it has not been strongly associated with bladder cancer
risk (Holick et al, 2007; World Cancer Research Fund and
American Institute for Cancer Research, 2007), and thus cannot
explain the association found with diabetes. In our study, the
association with diabetes was apparently, although not signifi-
cantly, stronger in overweight subjects compared to those with
regular weight. In any case, adjustment for BMI did not
meaningfully modify our risk estimates. As reported previously
(Zhu et al, 2013a, b), the association between diabetes and bladder
cancer was apparently stronger in men compared with that in
women, but this may be because of chance, giving the low number
of diabetic women in our study.
In our study, we were able to analyse the relation with duration
of diabetes, which has been examined in a limited number of
studies. Consistently with previous studies (MacKenzie et al, 2011;
Newton et al, 2013; Prizment et al, 2013), we found that the excess
risk of bladder cancer increases with duration of diabetes, although
a few other investigations reported no consistent trend in risk
(Atchison et al, 2011; Tseng, 2011).
The possible mechanisms explaining the association between
diabetes and bladder cancer are unclear. Insulin resistance and
hyperinsulinaemia, which characterise diabetes, have been shown
to stimulate tumour growth by increasing insulin-like growth
factor-1 levels, which in turn may stimulate cell proliferation
and inhibit apoptosis (Zhao et al, 2003; Vigneri et al, 2009).
Alternatively, diabetes increases the risk of urinary
tract infections (Chen et al, 2009), which are directly
associated with bladder cancer risk (La Vecchia et al, 1991;
Michaud, 2007).
Cases and controls in the present study came from comparable
catchment areas, were interviewed by uniformly trained inter-
viewers in their hospital settings, had an almost complete
participation rate, and were unaware of any particular hypothesis
relating diabetes to bladder cancer, thereby reducing the likelihood
of potential selection and recall bias. Diagnosis of diabetes and
other medical conditions was self-reported and we had no measure
of HbA1c levels for diabetic patients, thus some misclassification is
possible. However, reliability of information on diabetes provided
by hospital controls has been shown to be satisfactory in this
network of studies (Bosetti et al, 2001). Although hospital controls
may not be representative of the general population, the prevalence
of diabetes among our controls was consistent with estimates from
national population-based surveys (Asciutto et al, 2014; National
Institute of Health). We were also able to allow for major
confounding factors for bladder cancer, including, in particular,
careful allowance for tobacco. A further limitation of this study is
the lack of information on drugs used for diabetes control, which
have been shown to have variable effects on bladder cancer risk
(Soranna et al, 2012; Bosetti et al, 2013b). Moreover, we could not
distinguish between type 1 and type 2 diabetes, although most
(95%) of our subjects had a diagnosis after age 40 years, thus being
likely affected by type 2 diabetes mellitus.
In conclusion, our data support a role of diabetes in bladder
cancer aetiology, although some residual confounding by tobacco
smoking, BMI, or other unmeasured covariates may partly explain
the association observed.
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